Novavax Inc NVAX
We take great care to ensure that the data presented and summarized in this overview for NOVAVAX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVAX
View all-
Vanguard Group Inc Valley Forge, PA15.4MShares$130 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$99.5 Million0.0% of portfolio
-
Shah Capital Management9.82MShares$82.5 Million40.63% of portfolio
-
State Street Corp Boston, MA7.69MShares$64.6 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.94MShares$49.9 Million0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA3.5MShares$29.4 Million0.0% of portfolio
-
Bank Of Montreal Toronto, A62.45MShares$20.6 Million0.01% of portfolio
-
Coatue Management LLC New York, NY2.22MShares$18.7 Million0.11% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.06MShares$17.3 Million0.04% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny2MShares$16.8 Million0.06% of portfolio
Latest Institutional Activity in NVAX
Top Purchases
Top Sells
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at NVAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
James Patrick Kelly EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,906
-34.15%
|
$135,248
$8.04 P/Share
|
|
Dec 31
2024
|
James Patrick Kelly EVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+41.42%
|
-
|
|
Dec 31
2024
|
James F Young |
SELL
Open market or private sale
|
Direct |
5,400
-9.45%
|
$43,200
$8.0 P/Share
|
|
Dec 24
2024
|
James F Young |
SELL
Open market or private sale
|
Direct |
4,600
-7.45%
|
$36,800
$8.48 P/Share
|
|
Dec 13
2024
|
Rachel K. King |
SELL
Open market or private sale
|
Direct |
4,150
-21.93%
|
$37,350
$9.02 P/Share
|
|
Dec 11
2024
|
Mark J Casey EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,713
-30.34%
|
$101,704
$8.82 P/Share
|
|
Dec 11
2024
|
Mark J Casey EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,900
+50.0%
|
-
|
|
Oct 29
2024
|
Richard J Rodgers |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+21.03%
|
-
|
|
Aug 19
2024
|
John Trizzino EVP, CCO and CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-1.11%
|
$4,121
$13.9 P/Share
|
|
Aug 19
2024
|
John Trizzino EVP, CCO and CBO |
BUY
Exercise of conversion of derivative security
|
Direct |
655
+2.24%
|
-
|
|
Aug 16
2024
|
James Patrick Kelly EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,223
-7.81%
|
$14,676
$12.96 P/Share
|
|
Aug 16
2024
|
James Patrick Kelly EVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,367
+13.14%
|
$28,404
$12.96 P/Share
|
|
Jun 21
2024
|
James F Young |
SELL
Open market or private sale
|
Direct |
7,500
-10.83%
|
$105,000
$14.09 P/Share
|
|
Jun 18
2024
|
James F Young |
SELL
Open market or private sale
|
Direct |
7,500
-4.95%
|
$97,500
$13.95 P/Share
|
|
Jun 17
2024
|
Filip Dubovsky President, R&D |
SELL
Open market or private sale
|
Direct |
13,904
-8.79%
|
$194,656
$14.5 P/Share
|
|
Jun 17
2024
|
Filip Dubovsky President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
13,904
+7.73%
|
$83,424
$6.53 P/Share
|
|
Jun 12
2024
|
Margaret G Mcglynn |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+38.91%
|
-
|
|
Jun 12
2024
|
Richard Douglas |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+13.18%
|
-
|
|
Jun 12
2024
|
Gregg H Alton |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+38.91%
|
-
|
|
Jun 12
2024
|
Richard J Rodgers |
BUY
Exercise of conversion of derivative security
|
Direct |
6,670
+38.91%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 342K shares |
|---|
| Payment of exercise price or tax liability | 113K shares |
|---|---|
| Open market or private sale | 90.4K shares |